Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (10)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Suzuki, Y.
Right arrow Articles by Tajima, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Suzuki, Y.
Right arrow Articles by Tajima, T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Japanese Journal of Clinical Oncology 33:514-517 (2003)
© 2003 Foundation for Promotion of Cancer Research

Combination of Trastuzumab and Vinorelbine in Metastatic Breast Cancer

Yasuhiro Suzuki, Yutaka Tokuda, Yuki Saito, Masatoshi Ohta and Tomoo Tajima+

Department of Surgery, Tokai University School of Medicine, Isehara, Kanagawa, Japan

Background: Since the clinical introduction of trastuzumab (Herceptin®) for metastatic breast cancers that overexpress human epidermal growth factor receptor 2 (HER2), this anticancer agent has played an important role in breast cancer treatment. We examined the effects of trastuzumab and vinorelbine (Navelbine®) as a second- or third-line therapy in 24 patients whose HER2-positive tumors did not respond to or relapsed after administration of trastuzumab alone or in combination with taxane.

Methods: Trastuzumab was administered at 2 mg/kg (loading dose 4 mg/kg) once weekly and vinorelbine at 25 mg/m2 once weekly. The median treatment duration was 118.5 days (range, 22–351 days).

Results: The response rate was 42% (95% confidence interval (CI): 22%–63%). The adverse events of NCI-CTC grade 3 or above consisted of neutropenia in three patients; other adverse events, including vasculitis, generalized fatigue, anemia and thrombocytopenia, were grade 1 or 2. All adverse events were reversible after treatment withdrawal and were easily manageable.

Conclusion: A combination of trastuzumab and vinorelbine can be safely administered on an outpatient basis, and is useful in the treatment of patients with HER2-overexpressing metastatic breast cancer.

+ For reprints and all correspondence: Yutaka Tokuda, Bohseidai, Isehara, Kanagawa 259-1193, Japan. E-mail: tokuda{at}is.icc.u-tokai.ac.jp


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
G. K. Pansegrau, D. R. Grant, B. Norris, and K. A. Gelmon
Trastuzumab-Associated Peripheral Vascular Toxicity
J. Clin. Oncol., April 10, 2007; 25(11): 1438 - 1440.
[Full Text] [PDF]

Home page
 Ann OncolHome page
P. Papaldo, A. Fabi, G. Ferretti, M. Mottolese, A. M. Cianciulli, B. Di Cocco, M. S. Pino, P. Carlini, S. Di Cosimo, I. Sacchi, et al.
A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-positive disease
Ann. Onc., April 1, 2006; 17(4): 630 - 636.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
M. Toi, T. Saeki, K. Aogi, M. Sano, K. Hatake, T. Asaga, Y. Tokuda, S. Mitsuyama, M. Kimura, T. Kobayashi, et al.
Late Phase II Clinical Study of Vinorelbine Monotherapy in Advanced or Recurrent Breast Cancer Previously Treated with Anthracyclines and Taxanes
Jpn. J. Clin. Oncol., June 1, 2005; 35(6): 310 - 315.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.